Isto Biologics launched Fibrant Liberty allograft, a dry allograft mixture that integrates robust cortical fibers with mineralized cortical cancellous chips.
Upon hydration, the graft transforms into a pliable form that can be tailored to meet the precise needs of diverse surgical procedures. The longer and stronger fibers enable superior handling and create an intricate entanglement that prevents graft migration while preserving structural integrity.
Paired with a specially engineered fiber bundle, Fibrant Liberty utilizes an open-bore syringe design that delivers consistent and immediate hydration with the surgeon’s fluid of choice. The product is free from additives that could compromise bone content, thus allowing Fibrant Liberty to preserve the purity of the graft and foster optimal bone growth. Additionally, the inclusion of cortical cancellous chips enhances postoperative visualization and provides compression resistance to maintain the volume of the fusion mass.
Since acquiring TheraCell and their legacy TheraFuze DBF line in 2022, Isto Biologics has focused on enhancing the reimagined Fibrant line with a broad range of effective allograft solutions. “We are thrilled to introduce Fibrant Liberty as the latest addition in our Fibrant line,” stated Don Brown, CEO of Isto Biologics. “This launch underscores our commitment to advancing allograft solutions that significantly enhance patient outcomes and support healthcare professionals in their practice.”
Isto Biologics launched Fibrant Liberty allograft, a dry allograft mixture that integrates robust cortical fibers with mineralized cortical cancellous chips.
Upon hydration, the graft transforms into a pliable form that can be tailored to meet the precise needs of diverse surgical procedures. The longer and stronger fibers enable superior...
Isto Biologics launched Fibrant Liberty allograft, a dry allograft mixture that integrates robust cortical fibers with mineralized cortical cancellous chips.
Upon hydration, the graft transforms into a pliable form that can be tailored to meet the precise needs of diverse surgical procedures. The longer and stronger fibers enable superior handling and create an intricate entanglement that prevents graft migration while preserving structural integrity.
Paired with a specially engineered fiber bundle, Fibrant Liberty utilizes an open-bore syringe design that delivers consistent and immediate hydration with the surgeon’s fluid of choice. The product is free from additives that could compromise bone content, thus allowing Fibrant Liberty to preserve the purity of the graft and foster optimal bone growth. Additionally, the inclusion of cortical cancellous chips enhances postoperative visualization and provides compression resistance to maintain the volume of the fusion mass.
Since acquiring TheraCell and their legacy TheraFuze DBF line in 2022, Isto Biologics has focused on enhancing the reimagined Fibrant line with a broad range of effective allograft solutions. “We are thrilled to introduce Fibrant Liberty as the latest addition in our Fibrant line,” stated Don Brown, CEO of Isto Biologics. “This launch underscores our commitment to advancing allograft solutions that significantly enhance patient outcomes and support healthcare professionals in their practice.”
Copy to clipboard 
